Belgian drugmaker UCB (Euronext Brussels: UCB) has launched an awareness-raising campaign around brain-related illnesses such as Parkinson’s disease.
While many believe that Parkinson’s disease only causes motor symptoms such as tremor, stiffness and slowness, UCB is aiming to improve education around the non-motor symptoms such as sleep disturbance, mood disorders, gastro-intestinal problems and pain, which are a major cause of disability for people with the disease, and their carers.
More than 90% of people with Parkinson’s have non-motor symptoms, which can go unreported due to a lack of awareness that these are linked to the disease. In many cases, however, these symptoms are treatable.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze